Somalogic Inc (NASDAQ:SLGC) — Market Cap & Net Worth

$396.23 Million USD  · Rank #13286

Market Cap & Net Worth: Somalogic Inc (SLGC)

Somalogic Inc (NASDAQ:SLGC) has a market capitalization of $396.23 Million ($396.23 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13286 globally and #3225 in its home market, demonstrating a -1.60% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Somalogic Inc's stock price $19.06 by its total outstanding shares 188679008 (188.68 Million). Review SLGC liabilities breakdown to assess the company's total debt and financial obligations.

Somalogic Inc Market Cap History: 2026 to 2026

Somalogic Inc's market capitalization history from 2026 to 2026. Data shows growth from $3.60 Billion to $3.60 Billion (0.00% CAGR).

Somalogic Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Somalogic Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

No P/S ratio data available

Latest Price to Earnings (P/E) Ratio

No P/E ratio data available

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
No financial ratio data available

Competitor Companies of SLGC by Market Capitalization

Companies near Somalogic Inc in the global market cap rankings as of August 1, 2026.

Key companies related to Somalogic Inc by market ranking:

  • Veeva Systems Inc Class A (NYSE:VEEV): Ranked #980 globally with a market cap of $27.24 Billion USD.
  • Pro Medicus Ltd (AU:PME): Ranked #1931 globally with a market cap of $11.99 Billion USD ( AU$16.95 Billion AUD).
  • BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2123 globally with a market cap of $10.63 Billion USD.
  • Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2675 globally with a market cap of $7.62 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#980 Veeva Systems Inc Class A NYSE:VEEV $27.24 Billion $203.78
#1931 Pro Medicus Ltd AU:PME $11.99 Billion AU$162.21
#2123 BrightSpring Health Services, Inc. Common Stock NASDAQ:BTSG $10.63 Billion $59.71
#2675 Tempus AI, Inc. Class A Common Stock NASDAQ:TEM $7.62 Billion $43.87

Somalogic Inc Historical Marketcap From 2026 to 2026

Between 2026 and today, Somalogic Inc's market cap moved from $3.60 Billion to $ 3.60 Billion, with a yearly change of 0.00%.

Year Market Cap Change (%)
2026 $3.60 Billion --

End of Day Market Cap According to Different Sources

On Aug 1st, 2026 the market cap of Somalogic Inc was reported to be:

Source Market Cap
Yahoo Finance $396.23 Million USD
MoneyControl $396.23 Million USD
MarketWatch $396.23 Million USD
marketcap.company $396.23 Million USD
Reuters $396.23 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Somalogic Inc

NASDAQ:SLGC USA Health Information Services
Market Cap
$3.60 Billion
Market Cap Rank
#13286 Global
#3225 in USA
Share Price
$19.06
Change (1 day)
-0.31%
52-Week Range
$19.06 - $19.63
All Time High
$19.63
About

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in … Read more